Objectives: Our group has already demonstrated that patients' health-related quality of life (HRQL) improves in the first 6 months after their first appointment at memory assessment services (MASs), but the sustainability of such gains is unknown. We aimed to describe changes in patients' HRQL at 12 months after their first MAS appointment and to examine associations with patient and MAS characteristics.
| INTRODUCTION
Memory assessment services (MASs) have a central role in dementia care, providing assessment and diagnosis for new referrals, post-diagnostic support, and follow-up. [1] [2] [3] [4] The past decade has seen a significant increase in provision of, and investment in, these services. 5 Despite rapid expansion in service provision, evidence for the benefits of MASs in terms of patient outcomes is limited. 6 It is only recently that robust evaluation of the effectiveness of MASs has emerged. The largest published study of MAS patients to date, which followed up nearly 900 patients from a nationally representative sample of clinics across England, found that patients' health-related quality of life (HRQL) improves in the first 6 months after their first appointment at a MAS. 7 This finding is consistent with earlier small-scale studies, which suggested that MASs may be beneficial in the initial months after referral. 8, 9 However, evidence for patient outcomes beyond 6 months is currently lacking so the sustainability of such benefits is not known. It is also unknown whether any patient characteristics, use of anti-dementia drugs or psychosocial interventions, or characteristics of the MASs have an impact on outcomes beyond 6 months.
The aims of this study were as follows: (1) to describe the change in patients' HRQL over the first 12 months after the first MAS appointment; (2) to examine whether patient characteristics are associated with changes in HRQL; (3) to determine if the use of antidementia drugs and/or psychosocial interventions is associated with improved HRQL in those patients diagnosed with dementia; and (4) to investigate the extent to which characteristics of MASs are associated with patients' HRQL at 12 months.
2 | METHODS
| Sample
We randomly selected 80 MASs from all 212 clinics in England identified in the Royal College of Psychiatrists national audit. 5 Of these, 73
MASs took part in the study at baseline (2 sites did not participate, 5
sites recruited fewer than 6 patients each and were excluded), and 71 remained in the study at 12-month follow-up. The selected MASs were representative of all clinics in England in terms of patient volume, waiting times, and accreditation status. 5 Patients referred for a first appointment between September 2014 and April 2015 with sufficient English language to understand the consent process and questionnaires, and their informal caregivers were eligible for inclusion. Each site was asked to recruit up to 25 consecutive new patients. 
| Outcomes
The patient questionnaires at baseline and 12 months included measures of disease-specific (DEMQOL 12 ) and generic (EQ-5D-3L
)
HRQL. DEMQOL is a 28-item instrument with items scored on a 4-point response scale, with higher score indicating better HRQL. We used a scoring algorithm based on Rasch Measurement Theory to generate scores, 14 and for analysis the scores were linearly transformed to range from 0 to 100. The EQ-5D-3L has 5 items, each covering 1 domain: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. A summary EQ-5D-3L index score was calculated using value sets derived from a UK general population survey to weight and combine responses. 15 Informal caregivers completed proxy-reported instruments for assessing the disease specific (DEMQOL-Proxy
14
) and generic (EQ-5D-3L proxy 15 ) HRQL of the patient.
The primary outcomes in this study were changes in patients'
DEMQOL and DEMQOL-Proxy scores between first appointment (baseline) and 12-month follow-up. We also included self-and proxy-reported EQ-5D-3L index scores as secondary outcomes.
| Patient-level characteristics
Data on patients' socio-demographic characteristics (age; sex; ethnicity; socio-economic status based on patients' residential postcodes and quintiles of the national ranking of Index of Multiple Deprivation IMD scores 16 Process characteristics were as follows: waiting time to first appointment (categorised as ≤6 or >6 weeks, the recommended standard 20 ), length of first appointment, and number of follow-up appointments within the first year (categorised as ≤1 or > 1, ie, clinic followup complete by 12 months or ongoing).
| Statistical analysis
Patient and MAS characteristics were summarised as means and standard deviations (SDs) or percentages. We used chi-squared tests to compare the characteristics of respondents at 12 months with those of non-respondents. Change in each measure of HRQL was assessed using paired t-tests to compare mean scores at baseline and 12 months, for the whole sample of patients and by diagnosis.
We used multivariable linear regression to examine the relation- Multilevel linear regression models were used to examine the relationships between MAS characteristics and patient HRQL at 12 months. Models included all structural and process characteristics and were adjusted for patient-level variables and MAS as a random effect. Analyses were conducted on the full sample of patients, and on the sub-sample of patients diagnosed with dementia. We report results as adjusted differences in HRQL score with confidence intervals.
Due to the large number of tests conducted and associated risk of degree of certainty about any effects that are observed. 21 All analyses were conducted using Stata V.14 (StataCorp, College station, Texas, USA).
| Ethical approval
The 3 | RESULTS
| Sample characteristics
Of the 1346 patients and 970 caregivers eligible for follow-up, 702
(52%) patients and 452 (47%) caregivers completed questionnaires at 12 months (Supplementary Figure 1) . The mean time to follow-up was 12.8 months (SD 1.0), with 95% of participants followed up between 10 and 15 months. Participants who were followed up late (>15 months from baseline) were similar to other participants in regards age, sex, ethnicity, deprivation, cognitive function, number of comorbidities, and HRQL at baseline. The only difference was a higher proportion had an informal caregiver participate at baseline (94% versus 71%, P = 0.006).
The characteristics of study participants are summarised in Table 1 . Respondents at 12 months were similar to non-respondents in terms of ethnicity, deprivation, comorbidities, HRQL scores at baseline and diagnosis, but were slightly younger (mean age 77.3 versus 78.6 years), more likely to be male (52% versus 44% male) and had higher cognitive function at baseline (31% versus 26% in highest cognitive function category).
By 12 months after the first MAS appointment, 59% (n = 405) of patients had received a diagnosis of dementia, and 26% (n = 182) had received a diagnosis of mild cognitive impairment (MCI). A few (4%, n = 28) had a psychiatric, cerebrovascular (no dementia), or traumarelated diagnosis, and 11% (n = 75) had received no diagnosis, some of whom had no evidence of cognitive impairment at baseline.
| Change in HRQL over first 12 months
Between baseline and 12 months, self-reported HRQL (DEMQOL) in the whole study population increased by 3.5 points (95% CI 2.7 to 4.3) (effect size: 0.29 SD) ( Table 2) . While all diagnostic groups demonstrated an increase in HRQL, this increase was larger among those with a diagnosis of dementia (+4.8 points, 95% CI 3.8 to 5.9; effect size: 0.40 SD) than those with MCI (+1.9, 95% CI 0.6 to 3.2; effect size: 0.16 SD) or no diagnosis (+1.6, 95% CI −0.6 to 3.9; effect size: 0.13 SD). No change in self-reported generic HRQL (EQ-5D-3L) was detected. Numbers in bold indicate statistically significant difference between baseline and 12-month scores, P < 0.05. Although proxy-reported HRQL (DEMQOL-Proxy) for the whole sample did not change over 12 months, the mean score did increase in the sub-group of those with a diagnosis of dementia (+1.2, 95% CI 0.2 to 2.2; effect size 0.13 SD).
There was no change in proxy-reported EQ-5D-3L index score except among those with a diagnosis of MCI in whom it decreased slightly (−0.05, 95% CI -0.1 to −0.008; effect size: 0.17 SD).
| Patient characteristics and change in HRQL
Changes in self-and proxy-reported HRQL (DEMQOL and DEMQOLProxy) were not associated with any of the patient characteristics in adjusted analyses (Table 3 ). This was also the case with generic measures of HRQL (self-and proxy-reported EQ-5D-3L index scores;
results not presented).
| Associations between change in HRQL and interventions in patients with dementia
Of the patients with dementia and data on intervention use (of any kind), 183 (63%) had been prescribed anti-dementia drugs since receiving their diagnosis and 97 (33%) had used psychosocial interventions. Of these, 63 (22%) received both types of intervention.
The HRQL of patients with dementia improved regardless of whether or not they received interventions (Table 4) . For both anti-dementia drugs and psychosocial interventions, the improvements were larger among those using the interventions than those not, although the differences were not statistically significant: the DEMQOL score for those prescribed anti-dementia drugs increased over 12 months by 6.0 points, compared with 3.4 points among those not prescribed these drugs (P-value from Z-test = 0.06); and by 6.6 points among those using psychosocial interventions compared with 4.3 points among those not (P-value: 0.34). No interaction effect between antidementia drugs and psychosocial intervention was detected.
| MAS characteristics and patients' HRQL at 12 months
In the whole sample of patients, self-reported HRQL was not associated with any MAS characteristics in the adjusted analysis (Table 5) .
Among those participants who received a diagnosis of dementia, only 1 MAS characteristic was associated with change in HRQL: the presence of advisory and support staff (support workers, social workers, mental health workers, dementia advisers) in the multi-professional team was associated with larger improvement in self-reported HRQL (DEMQOL score + 4.3 points, 95% CI 0.9 to 7.8) ( Table 5) .
MAS characteristics were not associated with changes in proxyreported HRQL or with self-and proxy-reported generic measures of HRQL in adjusted analyses (results available as Supplementary Table   1 ). This was true both for the overall sample and among those with a diagnosis of dementia (Supplementary Table 2 ).
4 | DISCUSSION
| Main findings
One year after their first MAS appointment, the majority of patients had received a diagnosis of either dementia or MCI. For the whole sample of patients, the improvements in self-reported dementia-specific HRQL previously observed at 6 months were still evident at 12 months. We did not find improvements in generic HRQL measured using EQ-5D, but such generic measures often have poor construct validity among people with dementia, and the use of condition-specific measures is recommended. 22 Self-reported improvement in dementia-specific HRQL among those patients diagnosed with dementia was more than twice that among those with MCI or no diagnosis. Although a small improvement in proxy-reported HRQL was observed among those with dementia, this was not apparent in those without a diagnosis of dementia. The improvement among those diagnosed with dementia was greater in those treated with anti-dementia drugs or using psychosocial interventions, although these associations did not reach statistical significance at the 5% level.
There were no associations between structural characteristics of MASs and outcomes apart from, among those with dementia, the inclusion of advisory and support staff which was associated with larger improvements in self-reported HRQL. None of the process characteristics studied were associated with the outcomes.
| Strengths and limitations
This is the largest study of changes in HRQL among people referred to Adjusted differences and Bonferroni-corrected 95% confidence intervals (family-wise error rate of 0.05 for each model divided by number of tests, P = 0.003). Higher score indicates better health-related quality of life, HRQL. Adjusted for all structural and process characteristics, HRQL score at baseline, patient age, sex, ethnicity, deprivation, comorbidity, diagnosis, and MAS as a random effect. *Statistically significant at family-wise error rate < 0.05.
The study has 4 limitations. First, due to the absence of a control arm (of people with suspected dementia who were not referred to MASs), it is not possible to attribute the improvement in HRQL to attending a MAS. As there is a lack of clinical equipoise about the value of early intervention for dementia, it is not ethical to randomise people to delayed referral, and consequently data on the natural history of HRQL (without any intervention) are not available. However, longitudinal studies assessing HRQL of people with dementia (using dementia-specific measures of HRQL) generally report no mean change in self-reported HRQL and no change or a decline in proxyreported HRQL over periods of up to 3 years. [23] [24] [25] [26] [27] [28] [29] Second, the recruitment rate at baseline was 42%, and only half of participants responded at 12 months. Participants recruited into the study at baseline were slightly younger, more likely to be male and had slightly better cognitive function when compared with referrals who did not take part. 10 At follow-up, only 3 of 12 characteristics differed between respondents and non-respondents, and of those 3 only cognitive function at baseline was associated with changes in HRQL.
However, our analyses and previous studies indicate that better cognitive function at baseline is associated with a decrease in self-reported HRQL 23 ; therefore, given the higher proportion of respondents with mild impairment (MMSE>27) in our sample, any bias is likely to have led to a slight under-rather than over-estimate of the extent of improvement in self-reported HRQL.
Third, there may have been other patient factors associated with outcomes, which were not fully accounted for in our analyses of intervention use. For example, the presence of contraindications to commonly used anti-dementia drugs.
Fourth, in our analysis of MAS characteristics, some were difficult to standardise across services despite our efforts to verify responses via telephone follow-up (eg, whole time equivalent staff levels as individuals worked across multiple services). In addition, some data were based on staff's estimates of typical or mean values (eg, waiting time).
| Comparison with other studies
Data from the same cohort of MAS attendees showed that patients' self-reported HRQL increased by 3.4 points (0.28 SD) over the first 6 months from first appointment. 7 The current study shows that this improvement in HRQL is still evident after 12 months (3.5 points).
While the improvement in HRQL at 6 months had been the same across all diagnostic groups, at 12 months there was a larger improvement among those with dementia. That might suggest that the current design of MASs is only of benefit (as measured in terms of dementiaspecific HRQL) to those with MCI for the initial 6 months. Consistent with other longitudinal studies of people with dementia, we found that changes in HRQL were not associated with patients' socio-demographic characteristics at baseline. 24, 26, 28, 30, 31 One study reported declines in HRQL to be associated with the number of comorbidities, 32 but this was in a population of older adults in care homes, who had poorer general health than participants in our study.
Analysis of 6 month data had found that patients with dementia who received anti-dementia drugs reported that their HRQL was improved by 4.6 points on average (compared with 2.2 in the nontreated group). 7 At 12 months, this difference was still apparent but was not statistically significant due to the smaller sample size as a result of attrition.
As regards the impact of psychosocial interventions, the negative association detected at 6 months (change in DEMQOL score 2.4
points, compared with 3.8 in non-treated group) was no longer apparent at 12 months. The lack of a negative association at 12 months might indicate that the benefits of psychosocial interventions occur sometime after the initial diagnosis. This would be consistent with some qualitative studies which concluded that in people with earlystage dementia, confronting the challenges of memory loss can lead to despair and a struggle with acceptance of a diagnosis. 33 In addition, early interactions with professional staff can contribute to feelings of loss of autonomy: in a study of men with early-stage Alzheimer's Disease, the majority of participants described initially perceiving outside help as another symbol of the many losses associated with their diagnosis. 34 The same study described a longer-term and ongoing process of reconstructing a sense of self.
The positive effect of allied health professional staff on HRQL at 6 months 35 was no longer apparent at 12 months. However, this had been replaced by the apparent benefit of advisory and support staff at 12 months which lends weight to the idea that the benefits of different interventions vary over the course of a patient's journey following diagnosis. 
| Implications

